Drug Profile
Deimmunised Haemophilia A Therapeutic - Biotest AG
Alternative Names: Deimmunised FVIII-Tregitope; Haemophilia A Therapeutic Reduced Immunogenicity; HAT RILatest Information Update: 27 Apr 2022
Price :
$50
*
At a glance
- Originator Biotest AG
- Class Antihaemorrhagics; Blood coagulation factors; Recombinant proteins
- Mechanism of Action Factor VIII replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Haemophilia A
Highest Development Phases
- Preclinical Haemophilia
Most Recent Events
- 25 Apr 2022 Biotest AG has been acquired by Grifols
- 21 Jul 2020 Deimmunised Haemophilia A Therapeutic - Biotest-AG is available for licensing as of 21 Jul 2020. https://www.biotest.com/de/en/index.cfm
- 28 Jul 2018 No recent reports of development identified for research development in Haemophilia in Germany (Parenteral)